What is Zag Bio?
Zag Bio is at the forefront of microbial engineering, developing a novel class of therapeutics that utilize genetically modified bacteria to colonize the tumor microenvironment. Unlike traditional immunotherapies, the company's platform is designed to release therapeutic payloads directly at the site of the tumor, thereby minimizing systemic toxicity while maximizing immune system activation. This dual-action mechanism represents a significant advancement in the field of oncology, offering a potential paradigm shift for patients suffering from hard-to-treat solid tumors. Headquartered in San Francisco, the company integrates deep expertise in synthetic biology and immunology to refine its living medicine pipeline, aiming to provide durable, localized responses that overcome the limitations of current standard-of-care treatments.
How much funding has Zag Bio raised?
Zag Bio has raised a total of $80M across 1 funding round:
Series A
$80M
Series A (2025): $80M with participation from Sanofi, ABBVIE, Polaris Partners, Regeneron Pharmaceuticals, and JDRF T1D Fund
Key Investors in Zag Bio
Sanofi
A global biopharmaceutical leader focused on scientific innovation across immunology, oncology, and rare diseases, providing extensive resources for drug development.
ABBVIE
A research-driven biopharmaceutical company dedicated to addressing complex medical challenges through innovative therapies in oncology and immunology.
Polaris Partners
A venture capital firm specializing in backing transformational companies within the biotech and healthcare sectors, providing strategic coaching and operational support.
What's next for Zag Bio?
With the successful closure of this major strategic investment, Zag Bio is poised to scale its operational capabilities and advance its lead programs through the rigorous preclinical pipeline. The company's strategic roadmap focuses on validating its engineered bacteria platform in clinical settings, a critical step toward establishing its efficacy in human subjects. Given the involvement of major industry players, the company is likely to prioritize partnerships that facilitate rapid clinical development and regulatory navigation. As the firm moves into this next phase of growth, the focus will remain on optimizing its microbial delivery systems and expanding its intellectual property portfolio to maintain a competitive edge in the rapidly evolving landscape of synthetic biology and cancer therapeutics.
See full Zag Bio company page
